Expression of bcl-2 and bcl-X in bladder cancer

Journal of Urology

Volumn 159, Issue 4, 1998, Pages 1348-1353

  Kirsh, Edward J ^a   Baunoch, David A ^a   Stadler, Walter M ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Section of Urology   (United States)

Author keywords

bcl 2; bcl X; Bladder cancer; p53; pRb

Indexed keywords

ONCOPROTEIN; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UROTHELIUM;

EID: 0031920608     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63614-0     Document Type: Article

References (31)

1. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1997. CA. Cancer J Clin., 47: 5, 1997.
2. Soloway, M. S.: Intravesical therapy for bladder cancer. Urol Clin North Am., 15: 661, 1988.
3. Kiemeney, L. A., Witjes, J. A., Verbeek, A. L., Heijbroek, R. P. and Debruyne, F. M.: The clinical epidemiology of superficial bladder cancer. Dutch South- East Cooperative Urological Group. Br J Cancer, 67: 806, 1993.
4. Wright, C., Mellon, K., Johnston, P., Lane, D. P., Harris, A. L., Home, C. H. and Neal, D. E.: Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer, 63: 967: 1991.
5. Dalbagni, G., Presti, J. C., Jr., Reuter, V. E., Zhang, Z. F., Sarkis, A. S., Fair, W. R. and Cordon-Cardo, C.: Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer, Diagn. Mol. Pathol., 2: 4, 1993.
6. Fujimoto, K., Yamada, Y., Okajima, E., Kakizoe, T., Sasaki, H., Sugimura, T. and Terada, M.: Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res., 52: 1393, 1992.
7. Sidransky, D., Von Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S. R. and Frost, P.: Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252: 706, 1991.
8. Serth, J., Kuczyk, M. A., Bokemeyer, C., Hervatin, C., Nafe, R., Tan, H. K. and Jonas, U.: p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br. J. Cancer, 71: 201, 1995.
9. Spruck, C.: H. III, Ohneseit, P. F., Gonzalez-Zulueta, M., Esrig, D., Miyao, N., Tsai, Y. C., Lerner, S. P., Schmutte, C., Yang, A. S. and Cote, R.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784, 1994.
10. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J.: Accumulation of nuclear p53 and tumor progression in bladder cancer [see comments]. N. Engl. J. Med., 331: 1259, 1994.
11. Cordon-Cardo, C., Dalbagni, G., Saez, G. T., Oliva, M. R., Zhang, Z. F., Rosai, J., Reuter, V. E. and Pellicer, A.: p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer, 56: 347, 1994.
12. Presti, J. C., Jr., Reuter, V. E., Galan, T., Fair, W. R. and Cordon-Cardo, C.: Molecular genetic alterations in superficial and locally advanced human bladder cancer, Cancer Res., 51: 5405, 1991.
13. Kubota, Y., Miyamoto, H., Noguchi, S., Shuin, T., Kitamura, H., Xu, H. J., Hu, S. X. and Benedict, W. F.: The loss of retinoblastoma gene in association with c-myc and transforming growth factor-beta 1 gene expression in human bladder cancer. J Urol., 154: 371, 1995.
14. Cordon-Cardo, C., Wartinger, D., Petrylak, D., Dalbagni, G., Fair, W. R., Fuks, Z. and Reuter, V. E.: Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl. Cancer Inst., 84: 1251, 1992.
15. Logothetis, C. J., Xu, H. J., Ro, J. Y., Hu, S. X., Sahin, A., Ordonez, N. and Benedict, W. F.: Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl. Cancer Inst., 84: 1256, 1992.
16. Ishikawa, J., Xu, H. J., Hu, S. X., Yandell, D. W., Maeda, S., Kamidono, S., Benedict, W. F. and Takahashi, R.: Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas, Cancer Res., 51: 5736, 1991.
17. Campos, L., Rouault, J. P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J. P. and Guyotat, D.: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81: 3091, 1993.
18. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W., Hsieh, J. T., Tu, S. M. and Campbell, M. L.: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer, Cancer Res., 52: 6940, 1992.
19. Charlotte, F., A, L. H., Martin, N., Geleyn, Y., Nollet, M., Gaulard, P. and Zafrani, E. S.: Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am. J. Pathol., 144: 460, 1994.
20. Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B., Harris, A., Gatter, K. C. and Mason, D. Y.: bcl-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med., 329: 690, 1993.
21. Bilim, V., Tomita, Y., Kawasaki, T., Katagiri, A., Imai, T., Takeda, M. and Takahashi, K.: Prognostic value of bcl-2 and p53 expression in urinary tract transitional cell cancer [letter]. J. Natl. Cancer Inst., 88: 686, 1996.
22. Krajewska, M., Moss, S. F., Krajewski, S., Song, K., Holt, P. R. and Reed, J. C.: Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res., 56: 2422, 1996.
23. Sanda, M., Pearsall, C., Derrow, S., Charles, L., Montie, J., Clarke, M. and Wojno, K.: Transitional cell carcinoma is characterized by overexpression of bcl-x-l and is susceptible to apoptosis induction by adenovirus-mediated bcl-x-s gene transfer. 6th Annual Fall Symposium of the Society for Basic Urologic Research, 1996.
24. Esrig, D., Spruck, C. H. d., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S. C., Skinner, D. G., Jones, P. A. and Cote, R.: J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143: 1389, 1993.
25. Minn, A. J., Boise, L. H. and Thompson, C. B.: Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage, Genes Dev., 10: 2621, 1996.
26. Thompson, C. B.: Apoptosis in the pathogenesis and treatment of disease. Science, 267: 1456, 1995.
27. McConkey, D. J., Greene, G. and Pettaway, C. A.: Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res., 56: 5594, 1996.
28. Krajewski, S., Krajewska, M., Shabaik, A., Wang, H. G., Irie, S., Fong, L. and Reed, J. C.: Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res., 54: 5501, 1994.
29. Krajewski, S., Tanaka, S., Takayama, S., Schibler, M. J., Fenton, W. and Reed, J. C.: Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res., 53: 4701, 1993.
30. King, E. D., Matteson, J., Jacobs, S. C. and Kyprianou, N.: Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J. Urol., 155: 316, 1996.
31. Yoshimura, I., Kudoh, J., Saito, S., Tazaki, H. and Shimizu, N.: p53 gene mutation in recurrent superficial bladder cancer. J. Urol., 153: 1711, 1995.